ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
87.475
-0.23%
Bitcoin
62,726.30
-0.60%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Athira Pharma Inc (ATHA)

  7. Athira Pharma Inc (ATHA) News

Athira Pharma Inc

Athira Pharma Inc (ATHA)

Athena Gold Corporation
1.922
0.002
(0.10%)
Closed April 28 4:00PM
Delayed by 15 minutes
1.922
0.00
(0.00%)
After Hours: 7:23PM
Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

ATHA News

Official News Only

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
February 22 2024
ATHA (0.10%)

Form 8-K - Current report
Edgar (US Regulatory)
February 22 2024
ATHA (0.10%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 16 2024
ATHA (0.10%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 16 2024
ATHA (0.10%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 16 2024
ATHA (0.10%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 08 2024
ATHA (0.10%)

ATHA Discussion

View Posts
glenn1919 glenn1919 4 weeks ago
ATHA..............................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 2 months ago
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
👍️0
Whalatane Whalatane 2 months ago
4:22 PM ET 02/14/2024
http://archive.fast-edgar.com/20240214/A3BEF62C8M22CZZ2222M2ZZZ5PKQZ2U2X262
Filed on: February 14, 2024

Baker Bros position
-------
Kiwi
👍️0
Whalatane Whalatane 4 months ago
“The new year is off to a strong start with the completion of enrollment in our Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease (AD), which we expect will enable topline data readout from the study in the second half of 2024,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
“The potential of fosgonimeton as a treatment for AD is supported by the independent, unblinded interim efficacy and futility analysis of the first 100 subjects in the Phase 2/3 LIFT-AD study and the results from the exploratory Phase 2 ACT-AD clinical trial, which showed potential congruent improvements in biomarkers of neurodegeneration, inflammation and Alzheimer’s disease protein pathologies as well as measures of cognition and function.”

“The totality of data shared to date strengthens our confidence in and supports the potential of our small molecule approach to targeting the neurotrophic hepatocyte growth factor (HGF) system for diseases including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). The consistency of data from preclinical models across various neurodegenerative diseases and in Alzheimer’s patients suggests that our small molecule drug candidates may be neuroprotective, neurotrophic, procognitive and potentially disease-modifying. This includes our recently reported findings from the exploratory SHAPE Phase 2 clinical trial, the results of which showed positive effects on several cognitive measures in the fosgonimeton 40 mg dose group, which is the same dose being investigated in the LIFT-AD trial.”


Kiwi
👍️0
Whalatane Whalatane 4 months ago
ATHA their P2/3 Alzheimer trial now fully enrolled.
Data in about 9 mths
They had an interim analysis run by an independent DMC ....Did not stop for futility . DMC said increase size of trial to power for statistically significant results ....so trial likely to show benefit .
Question is ....will the degree of benefit be clinically relevant .
-------------
Kiwi
👍️0
Whalatane Whalatane 4 months ago
The Trade: Athira Pharma, Inc. (ATHA) Director Joseph Edelman acquired a total of 605,686 shares at an average price of $2.42. To acquire these shares, it cost around $1.46 million.
What's Happening: Athira Pharma (ATHA), last month, announced results from SHAPE Phase 2 clinical trial of fosgonimeton for the treatment of Parkinson's disease dementia and dementia with Lewy Bodies.
What Athira Pharma Does: Athira Pharma Inc (ATHA) is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration.

Kiwi
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
ATHA... what a bio beast running through the streets...watch the explosion on the horizon...
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
What a day…what a stock!!!
👍️0
great_tree great_tree 2 years ago
Any serious comments on their product vs. SAVA, CRTX, AVXL etc.?
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
ATHA pushing hard into close
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
ATHA bio beast is very mad. She wants to fill that gap
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
ATHA is ready to move big next week, the best bio taking on Alzheimers
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
ATHA starting to heat up..love this bio beast!!!
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ATHA another bio beast ready to beast
👍️0
maximumgriff maximumgriff 3 years ago
Girt prices
👍️0
crudeoil24 crudeoil24 4 years ago
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.
👍️0
crudeoil24 crudeoil24 4 years ago
Athira Pharma started at buy with $36 stock price target at Stifel Nicolaus.
👍️0

Your Recent History

NASDAQ
ATHA
Athira Pharma
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved